Neoplasms

Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture

Retrieved on: 
Thursday, May 13, 2021
Neoplasms, Cancer, Melanoma, Fibrosarcoma, Health, Medicine

Kinnate Biopharma will be the majority shareholder in the joint venture.

Key Points: 
  • Kinnate Biopharma will be the majority shareholder in the joint venture.
  • KIN-2787 is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor candidate being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors.
  • The joint venture will also pursue development of KIN-3248 for the Chinese market.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial

Retrieved on: 
Thursday, May 13, 2021
Lung cancer, Pancreatic cancer, Non-small-cell lung carcinoma, Adenocarcinoma, Cancer, Neoplasms, Clinical medicine

In the collaborations, Merus plans to support molecular screenings for eligible patients with pancreatic adenocarcinoma in Israel and Italy, and with non-small cell lung cancer (NSCLC) in Spain, aimed to identify the presence of NRG1 fusions.

Key Points: 
  • In the collaborations, Merus plans to support molecular screenings for eligible patients with pancreatic adenocarcinoma in Israel and Italy, and with non-small cell lung cancer (NSCLC) in Spain, aimed to identify the presence of NRG1 fusions.
  • plans to perform a nationwide campaign in Israel to raise awareness of the molecular screening offered by Merus for eligible pancreatic adenocarcinoma patients and availability of the eNRGy trial for eligible patients.
  • The Cl\xc3\xadnica Universidad de Navarra, based in Pamplona and Madrid, is a leading research hospital in Spain.
  • The eNRGy trial consists of three cohorts: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer; and NRG1+ other solid tumors.

Global Soft Tissue Sarcoma Markets, Epidemiology and Patient Flow Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 13, 2021
Managed care, Health, Sarcoma, Neoplasms, Clinical medicine, Soft-tissue sarcoma, Kaposi's sarcoma, Epithelioid sarcoma

b'The "Global Soft Tissue Sarcoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Soft Tissue Sarcoma Epidemiology and Patient Flow Analysis - 2021, provides Soft Tissue Sarcoma epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Soft Tissue Sarcoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Soft Tissue Sarcoma Epidemiology and Patient Flow Analysis - 2021, provides Soft Tissue Sarcoma epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Soft Tissue Sarcoma patients, history of the disease at the population level (Soft Tissue Sarcoma prevalence, Soft Tissue Sarcoma incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nSoft Tissue Sarcoma patient flow: Soft Tissue Sarcoma prevalence, diagnosed, and drug-treated patients\nDemographics: Soft Tissue Sarcoma patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Soft Tissue Sarcoma market sizing, assessing market potential, and developing drug forecast models\nIdentify Soft Tissue Sarcoma patients segments through age groups, gender, and disease sub-types\nEvaluate Soft Tissue Sarcoma market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210513005447/en/\n'

QSAM Biosciences Announces Submission of IND Application for CycloSam® with FDA

Retrieved on: 
Tuesday, May 4, 2021
Bone metastasis, Food and Drug Administration, Osteosarcoma, Bone tumor, Neoplasms, Cancer, Health

The IND submission was submitted fully electronically, was compliant with all current FDA electronic document requirements, and was accepted for review by the FDA.\n\xe2\x80\x9cThis IND submission is an important accomplishment for QSAM as we continue to advance the development of CycloSam for the treatment of several types of primary and metastatic bone cancers,\xe2\x80\x9d stated Douglas R. Baum, the Company\xe2\x80\x99s CEO and Co-Founder.

Key Points: 
  • The IND submission was submitted fully electronically, was compliant with all current FDA electronic document requirements, and was accepted for review by the FDA.\n\xe2\x80\x9cThis IND submission is an important accomplishment for QSAM as we continue to advance the development of CycloSam for the treatment of several types of primary and metastatic bone cancers,\xe2\x80\x9d stated Douglas R. Baum, the Company\xe2\x80\x99s CEO and Co-Founder.
  • This drug candidate utilizes an FDA approved radioisotope combined with a novel chelant that has demonstrated increased efficacy and decreased side effects in animal models.
  • Given these factors, management believes there is a strong pathway to commercialization.\nCycloSam\xc2\xae is cleared by the FDA under an investigator initiated IND to commence human dosing in patients with osteosarcoma and bone metastasis.
  • This is not an offering of securities and securities may not be offered or sold absent registration or an applicable exemption from the registration requirements.\n'

Profound Medical to Release First Quarter 2021 Financial Results on May 12 – Conference Call to Follow

Retrieved on: 
Wednesday, April 21, 2021
Anatomy, Branches of biology, Neoplasms, Anatomical pathology, Medical physics, Gynaecological neoplasia, Uterine fibroid, Osteoid osteoma, Sonalleve MR-HIFU, Osteoma, Prostate cancer, XC2

TULSA-PRO\xc2\xae is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient\xe2\x80\x99s natural functional abilities.

Key Points: 
  • TULSA-PRO\xc2\xae is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient\xe2\x80\x99s natural functional abilities.
  • Sonalleve\xc2\xae has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma.
  • Such statements are based on the current expectations of the management of Profound.
  • Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

Antiva Biosciences Appoints Clifford Samuel to Board of Directors

Retrieved on: 
Wednesday, April 21, 2021
Cancer, Medicine, Neoplasms, Papillomavirus, Infectious causes of cancer, Carcinogenesis, Carcinogens, Human papillomavirus infection, Papilloma, Precancerous condition

b'SOUTH SAN FRANCISCO, Calif., April 21, 2021 /PRNewswire/ --Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the appointment of Clifford Samuel to the company\'s board of directors.

Key Points: 
  • b'SOUTH SAN FRANCISCO, Calif., April 21, 2021 /PRNewswire/ --Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the appointment of Clifford Samuel to the company\'s board of directors.
  • Mr. Samuel\'s deep passion for global health and his commitment to universal patient access to novel therapies are well-aligned with our mission.
  • "\nMost recently Mr. Samuel served as the Senior Vice President, Global Patient Solutions at Gilead, which included responsibility for more than 140 countries.
  • I\'m excited to join the Antiva board and help their team to maximize the global reach of their product.

Gynesonics Announces Publication of Clinical Study Analysis Demonstrating Effectiveness of the Sonata System in Treating Submucous and Large Symptomatic Uterine Fibroids

Retrieved on: 
Thursday, April 8, 2021
Health, Medical devices, Consumer, Women, Surgery, General Health, Clinical trials, Clinical medicine, Medicine, Neoplasms, Gynaecological neoplasia, Uterine fibroid, Gynecological surgery, Uterine myomectomy, Surgical oncology, Interventional radiology, Heavy menstrual bleeding, Sonata System, Gynesonics

Among 197 women (with 534 treated fibroids), 86% of patients with only submucous fibroids and 81% of women with large fibroids (>5 cm) experienced bleeding reduction within 3 months post-ablation.

Key Points: 
  • Among 197 women (with 534 treated fibroids), 86% of patients with only submucous fibroids and 81% of women with large fibroids (>5 cm) experienced bleeding reduction within 3 months post-ablation.
  • Additional fibroid mapping of large fibroids with magnetic resonance imaging in the FAST-EU trial showed an average volume reduction of 68%.
  • Transcervical fibroid ablation with the Sonata system for treatment of submucous and large uterine fibroids.
  • Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.

FDA Grants Two New Breakthrough Device Designations for Natera's Signatera™ MRD Test

Retrieved on: 
Wednesday, March 24, 2021
Medicine, Clinical medicine, Branches of biology, DNA, Oncology, Anatomical pathology, Circulating tumor DNA, Neoplasms, Natera, Cancer, Liquid biopsy, CAPP-Seq

These new designations will support the development of Signatera through Phase III clinical trials as a companion diagnostic to two different cancer therapies.

Key Points: 
  • These new designations will support the development of Signatera through Phase III clinical trials as a companion diagnostic to two different cancer therapies.
  • "These two new Breakthrough Device Designations will help us accelerate our mission to bring life-saving diagnosis and treatment to cancer patients as early as possible."
  • Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer.
  • The test is available for both clinical and research use, and has been granted three Breakthrough Device Designations by the FDA for multiple cancer types and indications.

Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24

Retrieved on: 
Wednesday, March 17, 2021
Cancer, Neoplasms, Health, Oncology, Sarcoma, Anatomical pathology, Glioblastoma, Soft-tissue sarcoma, Lung cancer

We now have a number of exciting clinical investigations underway for LB-100, including three clinical trials and one pharmacology study.

Key Points: 
  • We now have a number of exciting clinical investigations underway for LB-100, including three clinical trials and one pharmacology study.
  • Our initial cancer targets are myelodysplastic syndrome, soft tissue sarcomas, small cell lung cancer, and glioblastoma.
  • A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off.
  • This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml .

Pediatric Neuroblastoma Treatment Market Research and Outlook - Global Trends, Growth Opportunities and Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 10, 2021
Health, Oncology, Pediatric cancers, Brain tumor, Neuroblastoma, Cancer, Blastoma, Neoplasms, Health

The "Pediatric Neuroblastoma Treatment Market Research and Outlook, 2020 - Trends, Growth Opportunities and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pediatric Neuroblastoma Treatment Market Research and Outlook, 2020 - Trends, Growth Opportunities and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Pediatric Neuroblastoma Treatment market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Pediatric Neuroblastoma Treatment market types and applications.
  • It is a focused study on Pediatric Neuroblastoma Treatment market space including global and regional eight-year forecasts for revenues as well as proffers detailed snapshots of country-wide Pediatric Neuroblastoma Treatment market revenues.
  • The Pediatric Neuroblastoma Treatment market report presents key trends and dynamics making an impact on the Pediatric Neuroblastoma Treatment companies across the Americas, Europe, Asia Pacific, and Other markets and provides innovative approaches to stay ahead of the competition in the opportunity-rich Pediatric Neuroblastoma Treatment market.